11 November 2021 
EMA/CHMP/598957/2021  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Noxafil 
posaconazole 
On 11 November 2021,  the Committee for Medicinal  Products for Human Use (CHMP)  adopted a 
positive opinion recommending a change to the terms of the marketing authorisation  for the medicinal 
product Noxafil. The marketing authorisation holder for this  medicinal product is Merck Sha rp & Dohme 
B.V. 
The CHMP has adopted an extension to the existing indications for Noxafil gastro-resistant tablets as 
follows:1 
Noxafil gastro-resistant tablets are indicated for use in the  treatment of the following fungal 
infections in adults (see sections 4.2 and 5.1): 
• 
Invasive aspergillosis 
Noxafil  gastro-resistant tablets  are indicated for use in the treatment  of the following 
fungal infections in paediatric  patients from 2 years of age  weighing more than  40 kg 
and adults (see  sections 4.2 and 5.1): 
• 
Invasive  aspergillosis in patients  with disease  that is refractory to ampho tericin B or 
itraconazole or in patients  who are  intolerant of these  medicinal products; 
• 
Fusariosis in patients with  disease that  is refractory to amphotericin B or in patients  who are 
intolerant of amphotericin B; 
•  Chromoblastomycosis and mycetoma in patients  with  disease that is refractory to itraconazole 
or in patients who are intolerant  of itraconazole; 
•  Coccidioidomycosis in patients with  disease that is refractory to amphotericin B, itraconazole or 
fluconazole or in patients who are intolerant of these medicinal products. 
Refractoriness is defined as progression of infection or failure to  improve after a minimum of 
7 days of prior therapeutic doses of effective antifungal therapy . 
1 New text as bold 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
 An agency of the European  Union       
© European Medicines Agency, 2021. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
Noxafil gastro-resistant tablets are also indicated  for prophylaxis of invasive fungal infections  in the 
following paediatric patients  from 2 years  of age  weighing more than  40 kg and adults 
(see  sections 4.2 and  5.1): 
• 
Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) 
or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are 
at high-risk of developing invasive fungal infections;  
•  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high -dose 
immunosuppressive therapy for graft versus host disease and who  are at high-risk of 
developing invasive fungal infections. 
The CHMP has also adopted an extension to  the existing indications for Noxafil concentrate for solution 
for infusion as follows:2 
Noxafil concentrate for solution for infusion is indicated for use in the treatment  of the  following 
fungal infections in adults (see sections 4.2 and 5.1): 
• 
Invasive aspergillosis 
Noxafil  concentrate for solution for infusion is indicated for use in the  treatment  of the 
following fungal infections in adult and paediatric  patients from 2 years of age  (see 
sections 4.2 and 5.1): 
• 
Invasive  aspergillosis in patients  with disease  that is refractory to amphotericin B or 
itraconazole or in patients  who are  intolerant of these  medicinal products; 
• 
Fusariosis in patients with  disease that  is refractory to amphotericin B or in patients  who are 
intolerant of amphotericin B; 
•  Chromoblastomycosis and mycetoma in patients  with  disease that is refractory to itraconazole 
or in patients who are intolerant  of itraconazole; 
•  Coccidioidomycosis in patients with  disease that is refractory to amphotericin B, itraconazole or 
fluconazole or in patients who are intolerant of these medicinal products.  
Refractoriness is defined as progression of infection or failure to  i mprove after a minimum of 
7 days of prior therapeutic doses of effective antifungal therapy . 
Noxafil concentrate for solution for infusion is also indicated for prophylaxis of invasive fungal 
infections in the following  adult and paediatric patients  from 2 years  of age  (see sections 4.2 
and 5.1): 
• 
Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) 
or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are 
at high-risk of developing invasive fungal infections;  
•  Hematopoietic stem cell transplant (HSCT) recipients who are undergoing high -dose 
immunosuppressive therapy for graft versus host disease and who  are at high -risk of 
developing invasive fungal infections. 
The CHMP also approved a new pharmaceutical form (gastro-resistant powder and solvent for oral 
suspension) for the paediatric population with  the following indications: 
2 New text as bold 
Noxafil  
EMA/CHMP/598957/2021  
Page 2/3 
 
 
 
 
 
Noxafil gastro-resistant powder and solvent for oral suspension is indicated for use in the 
treatment of the following fungal infections in  paediatric patients from 2 years of age (see 
sections 4.2 and 5.1): 
• 
Invasive aspergillosis in patients with  disease that is refractory to amphotericin  B or 
itraconazole or in patients who are intolerant of these medicinal products;  
• 
Fusariosis in patients with  disease that  is refractory to amphotericin B or in patients  who are 
intolerant of amphotericin B; 
•  Chromoblastomycosis and mycetoma in patients  with  disease that is refractory to itraconazole 
or in patients who are intolerant  of itraconazole; 
•  Coccidioidomycosis in patients with  disease that is refractory to amphotericin  B, itraconazole or 
fluconazole or in patients who are intolerant of these medicinal products.  
Refractoriness is defined as progression of infection or failure to  improve after a minimum of 
7 days of prior therapeutic doses of effective antifungal therapy . 
Noxafil gastro-resistant powder and solvent for oral suspension is indicated for prophylaxis of 
invasive fungal infections in the following paediatric patients from 2 years of age: 
• 
Patients receiving remission-induction chemotherapy for acute myelogenous leukaemia (AML) 
or myelodysplastic syndromes (MDS) expected to result in prolonged neutropenia and who are 
at high-risk of developing invasive fungal infections;  
•  Haematopoietic stem cell transplant  (HSCT) recipients who  are undergoing high -dose 
immunosuppressive therapy for graft versus host disease and who  are at high -risk of 
developing invasive fungal infections. 
Detailed recommendations for the use of this  product will be described in the updated summary of 
product characteristics (SmPC), which will  be published in the  revised European public assessment 
report (EPAR), and will be available in all official European Union la nguages after a decision on this 
change to the marketing authorisation  has been granted by the European Commission.  
Noxafil  
EMA/CHMP/598957/2021  
Page 3/3 
 
 
 
 
 
